MedTrace Logo

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-11-24

No results posted yet for this study

Summary

This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.

Conditions

  • Macular Edema
  • Radiation Retinopathy
  • Branch Retinal Vein Occlusion
  • Epiretinal Membrane
  • Central Serous Retinopathy With Pit of Optic Disc
  • Commotio Retinae
  • Vitritis

Interventions

DRUG

Episcleral Dexamethasone

Sustained Release Episcleral Dexamethasone

Sponsors & Collaborators

  • Targeted Therapy Technologies, LLC

    lead INDUSTRY

Principal Investigators

  • Theodore Leng, MD · Stanford Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2024-09-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04120311 on ClinicalTrials.gov